Skip to main content

A9001498: A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO‑ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTS

NCT03041792

A9001498: A 6-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO‑ARM, PARALLEL METHODOLOGY STUDY TO ASSESS THE EFFECT OF LIRAGLUTIDE ON FOOD INTAKE IN OBESE SUBJECTS

Principal Investigator

Sponsor

Pfizer

The purpose of this research study is to assess the effect of liraglutide administration on food intake in obese patients. Liraglutide is a medication that is FDA approved for the treatment of obesity, known as Saxenda Liraglutide has been evaluated in many clinical trials, in both participants with Type 2 diabetes and non-diabetic participants with obesity.